These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 17661848

  • 21. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modeling of contribution of DNA and RNA.
    Parkin NT.
    AIDS Rev; 2014; 16(3):160-71. PubMed ID: 25221990
    [Abstract] [Full Text] [Related]

  • 22. Influence of time and storage conditions on plasma HIV viral load measurements.
    Holguín A, Williams L, Castilla J, Soriano V.
    Antivir Ther; 1997 Dec; 2(4):265-8. PubMed ID: 11327446
    [Abstract] [Full Text] [Related]

  • 23. Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection.
    Uttayamakul S, Likanonsakul S, Sunthornkachit R, Kuntiranont K, Louisirirotchanakul S, Chaovavanich A, Thiamchai V, Tanprasertsuk S, Sutthent R.
    J Virol Methods; 2005 Sep; 128(1-2):128-34. PubMed ID: 15913797
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings.
    Knuchel MC, Tomasik Z, Speck RF, Lüthy R, Schüpbach J.
    J Clin Virol; 2006 May; 36(1):64-7. PubMed ID: 16431154
    [Abstract] [Full Text] [Related]

  • 26. Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load <50 copies/ml.
    Kupfer B, Matz B, Däumer MP, Roden F, Rockstroh JK, Qurishi N, Spengler U, Kaiser R.
    J Med Virol; 2007 Oct; 79(10):1440-5. PubMed ID: 17705170
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance.
    Buckton AJ, Bissett SL, Myers RE, Beddows S, Edwards S, Cane PA, Pillay D.
    J Antimicrob Chemother; 2008 Dec; 62(6):1191-8. PubMed ID: 18927229
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of 3 nucleic acid isolation methods for the quantification of HIV-1 RNA by Cobas Taqman real-time polymerase chain reaction system.
    Alp A, Hascelik G.
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):365-71. PubMed ID: 19232859
    [Abstract] [Full Text] [Related]

  • 31. Generation of dried tube specimen for HIV-1 viral load proficiency test panels: a cost-effective alternative for external quality assessment programs.
    Ramos A, Nguyen S, Garcia A, Subbarao S, Nkengasong JN, Ellenberger D.
    J Virol Methods; 2013 Mar; 188(1-2):1-5. PubMed ID: 23219930
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA.
    Elbeik T, Nassos P, Kipnis P, Haller B, Ng VL.
    J Clin Microbiol; 2005 Aug; 43(8):3769-71. PubMed ID: 16081908
    [Abstract] [Full Text] [Related]

  • 33. [Analysis of the results of the SEIMC External Quality Control Program for HIV-1 and HCV viral loads, 2007].
    Spanish Society of Infectious Disease and Clinical Microbiology (SEIMC)Programa Externo de Control de Calidad SEIMC, España., Orta Mira N, Guna Serrano Mdel R, Latorre Martínez JC, Ovies MR, Pérez JL, Gimeno Cardona C.
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 13():8-13. PubMed ID: 19100161
    [Abstract] [Full Text] [Related]

  • 34. Measurement of viral load by the automated Abbott real-time HIV-1 assay using dried blood spots collected and processed in Malawi and Mozambique.
    Erba F, Brambilla D, Ceffa S, Ciccacci F, Luhanga R, Sidumo Z, Palombi L, Mancinelli S, Marazzi MC, Andreotti M, Giuliano M.
    S Afr Med J; 2015 Nov 08; 105(12):1036-8. PubMed ID: 26792161
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.
    Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, Amellal B, Bennai Y, Peytavin G, Calvez V, Pialoux G, Murphy R, Katlama C.
    HIV Med; 2008 Oct 08; 9(9):738-46. PubMed ID: 18651858
    [Abstract] [Full Text] [Related]

  • 39. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, Corral A, Heneine W, de Mendoza C, García-Lerma JG.
    AIDS; 2007 Nov 30; 21(18):2503-11. PubMed ID: 18025887
    [Abstract] [Full Text] [Related]

  • 40. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C.
    J Antimicrob Chemother; 2008 Jun 30; 61(6):1344-7. PubMed ID: 18343806
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.